CD274 and non-small cell lung carcinoma: In an interim analysis of a phase III trial (PEARLS/KEYNOTE-091 study), one-year pembrolizumab treatment significant improved median DFS over placebo (53.6 versus 42.0 months; HR, 0.76; 95% CI, 0.63–0.91; P = 0.0014) in patients with stage IB-IIIA NSCLC as an adjuvant treatment following surgical resection (lobectomy or pneumonectomy), regardless of PD-L1 expression [34, 35].